Ipsen Regulated Information | Investor Relations

Regulated Information
Shareholders Meeting

Period

Filter by

Reset

Showing: 1 – 05 of 171 Regulated Information

Show

Sort

18 May 2026

Ipsen – April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital

18 May 2026

Ipsen initiates a new share buy-back program

13 May 2026

Ipsen S.A. – Evolution of the composition of the Board of Directors

13 May 2026

Annual General Meeting of Ipsen S.A. held on 13 May 2026

22 April 2026

$Download Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration$

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

1 2 3 4 … 35

Regulated Information

Filter

Ipsen – April 2026- Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen initiates a new share buy-back program

Ipsen S.A. – Evolution of the composition of the Board of Directors

Annual General Meeting of Ipsen S.A. held on 13 May 2026

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

We value your feedback